%0 Journal Article
%T Clinical Study of ¡°Lingqi Huangban Granule¡± in Treating Choroidal Neovascularisation in Pathologic Myopia
%A Bingwen Lu
%A Xingwei Wu
%A Lei Zhang
%J Chinese Medicine
%P 125-132
%@ 2151-1926
%D 2016
%I Scientific Research Publishing
%R 10.4236/cm.2016.74013
%X Objectives: To study the therapeutic effects of </span><span style=\"font-family:Verdana;\">¡°</span><span style=\"font-family:Verdana;\">Lingqi Huangban Granule</span><span style=\"font-family:Verdana;\">¡±</span><span style=\"font-family:Verdana;\"> (LQHB) combined with
intravitreal ranibizumab injection (IVR) for choroidal neovascularisation (CNV)
in pathologic myopia (PM).</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">Methods:
This was a prospective, comparative, interventional study. Eighty eyes of
eighty consecutive patients with myopic CNV were randomized into control group
(IVR, 40 eyes) and integrative therapy group (IVR + LQHB, 40 eyes), each with a
follow-up period of 12 months. IVR was given with an </span><span style=\"font-family:Verdana;\">¡°</span><span style=\"font-family:Verdana;\">on demand</span><span style=\"font-family:Verdana;\">¡±</span><span style=\"font-family:Verdana;\"> regimen (Pro re nata, PRN). Final best corrected visual acuity (BCVA)
and its change from baseline were the main outcome measures. Changes in optical
coherence tomography (OCT) and central retinal thickness (CRT) were the
secondary outcome measures.</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">Results:
BCVA of patients in the integrative group improved significantly (from 47.10</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">¡À</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">13.51 letters to 90.72</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">¡À</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">12.98 letter, P</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">&lt;</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">0.05), more than in the control group (from 42.90</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">¡À</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">13.18 letters to 69.18</span><span style=\"font-family:Verdana;\">¡À</span><span style=\"font-family:Verdana;\">13.21
letters, P</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">&lt;</span><span style=\"font-family:&quot;\"> </span><span style=\"font-family:Verdana;\">0.05) since the third month after the initial treatment to the end of the
follow-up. Mean OCT CRT reduced from 364.75</span><span
%K Pathological Myopia
%K Choroidal Neovascularisation
%K ¡°Lingqi Huangban Granule¡±
%K Ranibizumab
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=72140